Abstract 5316
Background
Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second leading cause of cancer-related death by 2030 (Rahib et al, 2014). The overall 5-year survival rate is currently less than 7%. Gemcitabine is used for patients who are not suitable for combination therapy, but the response is poor at less than 10% (Conroy et al, 2011). Gemcitabine efficacy is limited due to intrinsic or acquired resistance mechanisms associated with transport, activation and breakdown. NUC-1031, a phosphoramidate transformation of gemcitabine, is designed to overcome the three key resistance mechanisms responsible for a poor survival prognosis to gemcitabine. In a Phase I study, NUC-1031 was well tolerated and demonstrated anti-tumour activity across a wide range of advanced cancers, including PDAC (Blagden et al, ASCO 2015). This ongoing Phase III study is designed to compare NUC-1031 with gemcitabine as first-line treatment in patients with PDAC who are unsuitable for combination chemotherapy.
Trial design
First-line patients with metastatic PDAC are being randomised to either NUC-1031 (825 mg/m2) or gemcitabine (1000 mg/m2) on days 1, 8 and 15 of a 28-day cycle until disease progression. Patients unsuitable for combination chemotherapy with a PS of 0-2 are eligible. Over 125 patients have been randomised across more than 20 centres. To detect a hazard ratio of 0.705 between the two arms, 270 events must be obtained from 328 patients, assuming a median survival of 6 months in the control (gemcitabine) arm. The primary outcome measure is overall survival. Secondary outcome measures include progression free survival, objective response rate, disease control rate, quality of life and safety. Translational research will explore the use of biomarkers for predictive benefit of NUC-1031 over gemcitabine.
Clinical trial identification
ISRCTN16765355.
Legal entity responsible for the study
Clatterbridge Cancer Centre NHS Foundation Trust.
Funding
NuCana Biomed Ltd.
Editorial Acknowledgement
Not applicable.
Disclosure
D. Harrison Palmer, W. Greenhalf: Research grant, travel bursary: Nucana Biomed Ltd. J. Wadsley: Honoraria: AstraZeneca, Sanofi-Genzyme, Eisai, Bayern, celgene, Lilly, Novartis. Consultancy, Advisory: AstraZeneca, Sanofi-Genzyme, Eisai, Bayer, Celgene, Lilly, Novartis; Research funding: AstraZeneca, Sanofi-Genzyme. J. Neoptolemos: Travel grant: Nucana Biomed Ltd. J.W. Valle, H. Wasan: Research funding: Nucana Biomed Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
1978 - FAM115c that upregulates proliferation and invasion under hypoxia could be a predictive biomarker for pancreatic cancer.
Presenter: Kiyoshi Saeki
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3682 - Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC)
Presenter: Annikka Weissferdt
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3319 - Tumor-infiltrating CD3+ lymphocytes and ICOS+ T-cells predict a favorable survival in resected esophageal squamous cell carcinoma
Presenter: Min Hee Hong
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5130 - Chemokine receptor CXCR7 expression, function and clinical implications in head and neck squamous cell carcinoma
Presenter: Myung-Won Lee
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4483 - Assessment of PD-1/PD-L1 colocalization in hepatocellular carcinoma (HCC) using bright-field double labeling and quantitative digital image analysis
Presenter: Thomas Mrowiec
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1175 - Pulmonary tumor thrombotic microangiopathy (PTTM): 24 case series and its criteria for pathological diagnosis.
Presenter: Naoko Sato
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1359 - Autofluorescence: a new marker for identifying cancer stem cells (CSCs) in primary tumors
Presenter: Miriam López Gómez
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2651 - NACC1 as a target of microRNA-331-3p regulates cell proliferation in urothelial carcinoma cells
Presenter: Kohei Morita
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2233 - Somatic-stem transition of tumor cells is a key link in the metastasis
Presenter: Nicolai Litviakov
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2601 - Profile of individuals who never undergo colorectal cancer screening
Presenter: Jérôme Viguier
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract